Literature DB >> 10739826

Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.

S Suissa1, W O Spitzer, B Rainville, J Cusson, M Lewis, L Heinemann.   

Abstract

The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers. Data from a Transnational case-control study were used to assess the risk of VTE for the latter patterns of use, while accounting for duration of use. Over the period 1993-1996, 551 cases of VTE were identified in Germany and the UK along with 2066 controls. Totals of 128 cases and 650 controls were analysed for repeat use and 135 cases and 622 controls for switching patterns. The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills. We conclude that second and third generation agents are associated with equivalent risks of VTE when the same agent is used repeatedly after interruption periods or when users are switched between the two generations of pills. These analyses suggest that the higher risk observed for the newer OC in other studies may be the result of inadequate comparisons of pill users with different patterns of pill use.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739826     DOI: 10.1093/humrep/15.4.817

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  12 in total

1.  Third generation oral contraceptives.

Authors:  D C Skegg
Journal:  BMJ       Date:  2000-07-22

2.  Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.

Authors:  J M Kemmeren; A Algra; D E Grobbee
Journal:  BMJ       Date:  2001-07-21

Review 3.  Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.

Authors:  Lamberto Manzoli; Corrado De Vito; Carolina Marzuillo; Antonio Boccia; Paolo Villari
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

4.  Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors.

Authors:  Phyo T Htoo; John B Buse; Mugdha Gokhale; M Alison Marquis; Virginia Pate; Til Stürmer
Journal:  Eur J Clin Pharmacol       Date:  2016-05-10       Impact factor: 2.953

Review 5.  A pathway to improved prospective observational post-authorization safety studies.

Authors:  Victor A Kiri
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

6.  Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First-Time Users and Restarters.

Authors:  Natasha Larivée; Samy Suissa; Janie Coulombe; Vicky Tagalakis; Kristian B Filion
Journal:  Drug Saf       Date:  2017-07       Impact factor: 5.606

Review 7.  Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.

Authors:  I F Godsland; U Winkler; O Lidegaard; D Crook
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 8.  Safety of a new oral contraceptive containing drospirenone.

Authors:  Lothar A J Heinemann; Jürgen Dinger
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism.

Authors:  Ulla M Ågren; Marjatta Anttila; Kristiina Mäenpää-Liukko; Maija-Liisa Rantala; Hilkka Rautiainen; Werner F Sommer; Ellen Mommers
Journal:  Eur J Contracept Reprod Health Care       Date:  2011-12       Impact factor: 1.848

10.  European active surveillance study of women taking HRT (EURAS-HRT): study protocol [NCT00214903].

Authors:  Juergen C Dinger; Lothar A J Heinemann
Journal:  BMC Womens Health       Date:  2006-01-17       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.